Oxford Bioscience Partners

Oxford BioMedica is a UK‑based biopharmaceutical company founded in 1995 and headquartered in Oxford that specializes in the development and manufacturing of gene and cell‑based therapies, including lentiviral vector platforms and therapeutic programmes for ophthalmology, oncology and central nervous system disorders. The company operates proprietary technology platforms such as its LentiVector® system to support clinical‑stage and partner‑led therapeutic development, collaborating with pharmaceutical and biotech partners to advance gene therapy candidates. Oxford BioMedica’s activities span internal research programmes and contract development and manufacturing services (CDMO) for external clients, providing scalable viral vector production capabilities. Its work includes advancing clinical trials and regulatory engagements for its own pipeline while supporting partners’ clinical and commercial goals. The firm emphasizes applied biotechnology innovation and translational science to address serious diseases.